The ZIP6/ZIP10 heteromer is essential for the zinc-mediated trigger of mitosis by Nimmanon, Thirayost et al.
Vol.:(0123456789) 
Cellular and Molecular Life Sciences 
https://doi.org/10.1007/s00018-020-03616-6
ORIGINAL ARTICLE
The ZIP6/ZIP10 heteromer is essential for the zinc‑mediated trigger 
of mitosis
Thirayost Nimmanon1 · Silvia Ziliotto2 · Olivia Ogle2 · Anna Burt2 · Julia M. W. Gee2 · Glen K. Andrews3,4 · Pete Kille5 · 
Christer Hogstrand6 · Wolfgang Maret6 · Kathryn M. Taylor2 
Received: 12 February 2020 / Revised: 22 July 2020 / Accepted: 7 August 2020 
© The Author(s) 2020
Abstract
Zinc has been known to be essential for cell division for over 40 years but the molecular pathways involved remain elusive. 
Cellular zinc import across biological membranes necessitates the help of zinc transporters such as the SLC39A family of 
ZIP transporters. We have discovered a molecular process that explains why zinc is required for cell division, involving two 
highly regulated zinc transporters, as a heteromer of ZIP6 and ZIP10, providing the means of cellular zinc entry at a specific 
time of the cell cycle that initiates a pathway resulting in the onset of mitosis. Crucially, when the zinc influx across this 
heteromer is blocked by ZIP6 or ZIP10 specific antibodies, there is no evidence of mitosis, confirming the requirement for 
zinc influx as a trigger of mitosis. The zinc that influxes into cells to trigger mitosis additionally changes the phosphorylation 
state of STAT3 converting it from a transcription factor to a protein that complexes with this heteromer and  pS38Stathmin, 
the form allowing microtubule rearrangement as required in mitosis. This discovery now explains the specific cellular role 
of ZIP6 and ZIP10 and how they have special importance in the mitosis process compared to other ZIP transporter family 
members. This finding offers new therapeutic opportunities for inhibition of cell division in the many proliferative diseases 
that exist, such as cancer.
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Introduction
Zinc is essential for life [1] and as such has indispensable 
roles in most biological systems. At least 10% of the human 
proteome are zinc-binding proteins [2], and more than 3% of 
all genes encode proteins with zinc finger domains. Accord-
ingly, zinc plays a vital role in processes that are essential for 
cell survival, including signal transduction, gene expression, 
meiosis [3], immune functions [4], control of apoptosis, 
and cell cycle progression [5]. Zinc is vital during different 
cell cycle stages [6–8] as well as indispensable for passage 
through G2/M [8], suggestive of a regulatory role for zinc 
in mitotic entry. Furthermore, zinc has been known for over 
40 years to be crucial for cell division, as established by 
demonstration of a zinc-dependent step in the G2 stage of 
the cell cycle [9] and how zinc was essential for progression 
from G2 to mitosis [10], confirming the ability of zinc to 
reverse a divalent cation chelating agent induced suppression 
of cell cycle progression [11], although the exact molecular 
mechanism is still unknown.
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Despite many years of study of the role of zinc in 
enzymes and transcription factors, it has more recently been 
classified as an intracellular second messenger, transducing 
an extracellular stimulus into intracellular fluctuations of 
zinc ions that affect signalling cascades [12]. One pathway 
involves the release of zinc from a store in the endoplasmic 
reticulum [13] which activates multiple downstream path-
ways required to promote cell survival and growth.
Due to its role in cell proliferation, zinc has been inves-
tigated in cancer for many years. Serum zinc can decrease 
in cancer [14–17] whereas zinc within the cancer tissue is 
often elevated compared to normal tissue perhaps reflecting 
the higher requirement for growth [18–20]. One exception 
to this is prostate cancer where the zinc is decreased [21]. 
Accordingly, chelating zinc has been explored as a means 
to stop proliferative growth of cancer tissues [22]. The addi-
tional zinc seen in cancers is usually supplied by various 
zinc transporters from the SLC39A family [23] [24–26]. 
Two close homologues within this family, ZIP6 (SLC39A6, 
also known as LIV-1) and ZIP10 (SLC39A10) [27, 28], 
with a 43.5% sequence identity, are on the same clade of 
the ZIP family phylogenetic tree [29] and have both been 
independently implicated in cancer [23, 29]. ZIP6 was first 
discovered as an oestrogen-regulated gene [30] present in 
breast cancers with lymph node involvement [31] and more 
recently used as a biomarker of oestrogen-receptor-positive 
luminal-type-A breast cancer [32, 33], a relationship con-
firmed both in cell lines and clinical material [34]. ZIP10 
has also been connected to cancer progression as a marker of 
metastatic breast cancer [35], an indicator of aggressiveness 
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of renal cell carcinoma [36] and associated with the expres-
sion of oestrogen receptor, ERBB3 and STAT3 in clinical 
breast cancer [34]. Interestingly, STAT3 is also known to 
increase the expression of ZIP6, a protein promoting cell 
migration [23, 37].
The observed similarity between ZIP6 and ZIP10 is rein-
forced by our recent demonstration of a ZIP6/ZIP10 heter-
omer [29]. This ZIP6/ZIP10 heteromer has a functional role 
in epithelial-mesenchymal transition (EMT), a fundamental 
event during gastrulation and cancer metastasis enabling 
individual cells to lose their cell–cell adherence, allowing 
cell rounding and detachment. Removal of either the ZIP10 
gene [29] or the ZIP6 gene [38] produces an identical phe-
notype in zebrafish gastrulation, causing EMT by removal 
of the adherence protein E cadherin (CDH1).
Grouping together the fact that no mechanism exists to 
explain the obligatory zinc required for mitosis and that 
both ZIP6 and ZIP10 cause cell rounding, the first step in 
the mitotic pathway, we examined whether these transport-
ers have any function in mitosis. Here we reveal how the 
zinc influx across the ZIP6/ZIP10 heteromer has a crucial 
purpose to initiate mitosis. Furthermore, we demonstrate 
the essential role of the ZIP6/ZIP10 heteromer in driving 
mitosis by the ability of our ZIP6/ZIP10 blocking antibod-
ies to completely prevent mitotic entry, even in the presence 
of agents that cause mitosis. Additionally, we determine 
important interacting proteins in this pathway by dem-
onstrating that the ZIP6/ZIP10 heteromer interacts with 
both  pS727STAT3, the phosphorylation of which is zinc-
dependant, and  pS38Stathmin, a known regulator of mitotic 
entry [39]. These data together define how zinc initiates the 
mitotic pathway and opens a new research avenue for novel 
therapeutic targets for diseases whose phenotypes include 
increased cell proliferation, such as cancer.
Results
The requirement of ZIP6 and ZIP10 for mitosis
The ZIP6 protein is not only highly regulated in cells but also 
responsible for causing cell rounding [23], an essential early 
component of mitosis. Using antibodies with epitopes on the 
extracellular N-terminus, both ZIP6 (red) and ZIP10 (green) 
are visible preferentially on the outside of non-permeabilised 
mitotic cells (Fig. 1a, white arrows) while generally absent 
from non-mitotic cells. Interestingly, all the ZIP6 and ZIP10 
positive cells are in the prophase stage of mitosis with the 
exception of one of the ZIP10 positive cells (Fig. 1a, top 
right) which is in metaphase, consistent with the presence of 
the relevant N-terminal sections at this stage of mitosis. The 
number of mitotic cells is enhanced by 20 h of nocodazole 
treatment, an agent that blocks microtubule polymerisation, 
as judged by FACS cell cycle analysis, which demonstrates 
an increased number of cells in G2/M in the whole popula-
tion (Fig. 1b) and in the non-adherent cells after mitotic 
shake off (Fig. 1c). Using these conditions we saw signifi-
cantly increased levels of both ZIP6 and ZIP10 in mitosis, as 
judged by increased  pS10HistoneH3 (Fig. 1d) in nocodazole 
treated samples compared to untreated control conditions. 
The 68 kDa band represents the N-terminally cleaved and 
active form of ZIP6 located on the plasma membrane [23], 
as recognised by the N-terminal directed antibody, ZIP6-Y 
(with epitope downstream of this cleavage site), and also the 
ZIP6-SC antibody, which recognises the cytoplasmic loop 
between TM3-4 [23]. ZIP10 undergoes N-terminal ectodo-
main shedding in the presence of nocodazole, represented 
by a decrease in the full-length protein and an increase in 
a 45 kDa fragment, corresponding to a large portion of the 
N-terminus, as recognised by the N-terminal ZIP10B anti-
body. The epitope of the ZIP10S antibody recognises the 
Fig. 1  The ZIP6/ZIP10 heteromer is increased in mitosis. a Non-
permeabilised Mitotic MCF-7 cells (arrow) have increased staining 
for ZIP6 (red, ZIP6-Y antibody) and ZIP10 (green, ZIP10B anti-
body) on the plasma membrane in contrast to the non-mitotic cells. 
Nuclei stained blue with DAPI. b, c FACS cell cycle analysis con-
firms the increase compared to control in the G2/M population in 
nocodazole-treated cells (b) as well as the increase in non-adherent 
cells collected after mitotic shake-off (c), compared to the adher-
ent cells from the same dishes. Results of three independent experi-
ments are demonstrated as mean ± SD. Statistical significance is 
determined by Student’s t test.***p < 0.001. d MCF-7 cells treated 
with nocodazole for 20 h have increased mitosis as judged by mitotic 
marker  pS10HistoneH3 as shown from a representative blot of more 
than three experiments. ZIP6 is significantly increased in mitotic 
cells and the active N-terminal-cleaved form of ZIP6 as a 68  kDa 
band is recognised by both ZIP6 antibodies (ZIP6-Y recognises 
N-terminus and ZIP6-SC recognises the cytoplasmic loop between 
TM3-4). ZIP10 undergoes cleavage in mitosis; Using the N-termi-
nal antibody ZIP10B the full length protein (105 kDa) decreased in 
the nocodazole-treated population and the smaller cleaved fragment 
increased significantly (45  kDa). Using the cytoplasmic loop anti-
body ZIP10S, an increase in the 60 kDa band was observed in mito-
sis which corresponded to the remainder of ZIP10 after removal of 
some of the N-terminus. Statistics (student t test) were compared to 
control. e FACS cell cycle analysis of transfected cells, divided into 
adherent and non-adherent populations after mitotic shake off show-
ing that transfection with ZIP6 or ZIP10 increased the cells in G2/M 
whether from the adherent on nonadherent populations. Results of at 
least three independent experiments are shown as mean ± SD Statisti-
cal significance comparing results to control samples was performed 
using ANOVA with Dunnett post-hoc and is shown as ***(p < 0.01) 
or ***(p < 0.001). f Proximity ligation assay (PLA) using ZIP6-Y 
and ZIP10B antibodies in nocodazole-treated MCF-7 cells, produces 
significantly increased dots (red) in mitotic cells (white arrows) com-
pared to non-mitotic cells. Nuclei stained with DAPI (blue). Repre-
sentative picture of quantitative measurements from at least 6 images 
of 25 stacks taken 0.3 μm apart from 3 independent experiments are 
demonstrated as mean ± standard error. Statistical significance was 
compared between mitotic and non − mitotic cells using ANOVA 
with Dunnett post-hoc and is shown as ***p < 0.001. Scale bar, 
25 μm
◂
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cytoplasmic loop between TM3-4 and therefore was able to 
recognise an increase in the 60 kDa band which represents 
the full length ZIP10 after part of the N-terminus has been 
cleaved. Furthermore, as we had previously discovered that 
transfecting cells with ZIP6 or ZIP10 increased the pop-
ulation of mitotic cells twofold [29], we expanded this to 
incorporate a mitotic shake off, enabling enrichment of the 
non-adherent, loosely attached population of mitotic cells. 
Examining the adherent cell populations, we demonstrate 
an increase in mitotic cell number in cells transfected with 
ZIP6 or ZIP10 (Fig. 1e) compared to LacZ control or ZIP7, 
used as a control ZIP protein. This increase in mitotic cell 
number was also seen in non-adherent cells after transfection 
with ZIP6 or ZIP10 (Fig. 1e) compared to controls, with the 
non-adherent ZIP6 transfected cells increasing their mitotic 
cell number fourfold. This data confirms the role of ZIP6 
and ZIP10 in initiating mitosis.
We next examined the binding of ZIP6 and ZIP10 in 
mitotic cells using proximity ligation assay, a quantitative 
method that generates red fluorescent dots if two molecules 
are close enough to be likely to interact [13]. Using this 
method, we show that ZIP6 and ZIP10 heteromers exist pref-
erentially in mitotic cells (Fig. 1f, white arrows) compared 
to non-mitotic cells and controls (supplementary Fig. A).
We then hypothesised that our ZIP6-Y or ZIP10B anti-
bodies, recognising the extracellular N-termini of ZIP6 or 
ZIP10, respectively, are able to block the zinc transport 
across the ZIP6/ZIP10 heteromer and thus prevent mitosis 
initiation. In order to test this, we first treated cells with noc-
odazole to demonstrate the increased percentage of mitotic 
cells, as judged by the number of  pS10HistoneH3 positive 
cells (Fig. 2, red). Subsequent treatment of cells with either 
our ZIP6-Y (Fig. 2a) or ZIP10B (Fig. 2b) antibody (both 
N-terminal epitopes) in addition to nocodazole significantly 
reduced the number of cells in mitosis in an antibody con-
centration-dependant manner (Fig. 2a, b, graphs), suggesting 
the ability of our antibodies to indeed block ZIP6/ZIP10 
heteromer mediated zinc influx. Furthermore, addition of 
the relevant IgG at 4 μg/ml (mouse as control for ZIP6-Y) 
or 10.5 μg/ml (rabbit as control for ZIP10B) to nocodazole 
treated cells (Fig. 2c) had no effect on the mitotic index 
of the cells, confirming a ZIP6/ZIP10-dependant effect. 
The role of ZIP6 and ZIP10 in mitosis is also relevant to 
non-cancerous cells, as treatment with both the ZIP6-Y 
and ZIP10B antibodies inhibits mitosis in NMuMG (nor-
mal mouse mammary gland cells) (Fig. 2d). This result was 
also reproduced in two triple negative (ER-, PR- and Her2-) 
breast cancer cell lines, MDA-231 (Fig. 3a) and MDA-436 
(Fig. 3b).
To confirm that blocking ZIP6 did not work by stabilis-
ing the microtubules and thus helping the cells to overcome 
the nocodazole block, we repeated this experiment in the 
absence of nocodazole. In order to achieve this, we partially 
synchronised the cells by serum withdrawal for 24 h and 
observed that cells entered mitosis 30 h later. Addition of 
the ZIP6-Y antibody to these synchronized cells significantly 
decreased mitosis (Fig. 3c) in the absence of nocodazole. 
Additional confirmation that nocodazole was not involved 
was obtained by cell treatment with ZIP6-Y or ZIP10B anti-
body for 4 days (Fig. 3d) demonstrating the ability of the 
ZIP6/ZIP10 heteromer blocking antibodies to significantly 
suppress cell growth and confirming the requirement of 
ZIP6/ZIP10-mediated zinc influx to trigger mitosis.
We next confirmed an increase of intracellular zinc 
ions in mitotic cells (Fig. 3e), by imaging zinc using the 
zinc-sensitive fluorescent agent Fluozin-3. White arrows 
indicate mitotic cells which all had increased fluorescence 
consistent with an increase in available free  Zn2+ ions. A 
significant increase in  [Zn2+]i in mitotic cells compared to 
non-mitotic cells was confirmed by FACS analysis, separat-
ing the mitotic cells using  pS10HistoneH3 (Fig. 3f). Fur-
thermore, after mitotic shake off, we observed a threefold 
increase in Fluozin-3 fluorescence in non-adherent cells 
(Fig. 3g) which were enriched with mitotic cells, as 90% 
had 4 N DNA content (Fig. 1c) compared to 48% for adher-
ent cells. We also show an increase of  [Zn2+]i in the mitotic 
cells of MCF-7 cells that had been treated with nocodazole 
for 20 h (Fig. 3h), by imaging zinc using the zinc-sensitive 
fluorescent agent Fluozin-3. Similarly, cells treated with 
nocodazole and additionally either ZIP6 or ZIP10 antibody 
also showed increased green fluorescence in mitotic cells, 
although the overall number of mitotic cells present in the 
antibody treated samples was much less, consistent with the 
results shown in Fig. 2 and suggestive that cells require zinc 
influx before they can progress to mitosis.
The ZIP6/ZIP10 heteromer binds phosphorylated 
STAT3  (pS727STAT3) in mitosis
We observed that when ZIP6 was enriched in rounded 
mitotic cells (Fig. 4a), these cells also contained  pS727STAT3 
(Fig. 4a). We confirmed a significantly elevated  pS727STAT3 
in mitosis (Fig. 4b), by Western blot with a concurrent 
reduction of  pY705STAT3 when cells had been treated with 
nocodazole. Furthermore, we confirmed that zinc treatment 
for 20 min reduces the amount of  pY705STAT3, as observed 
by others [40], and additionally increases the amount of 
 pS727STAT3 (Fig. 4c), demonstrating a reciprocal relation-
ship between  pY705STAT3 and  pS727STAT3.
In order to identify the relevance of  pS727STAT3 to 
the mechanism of mitosis initiation, we next investigated 
whether this form of STAT3 was bound to ZIP6 or ZIP10 
during mitosis using proximity ligation assay. We were able 
to demonstrate significant binding of  pS727STAT3 to both 
ZIP6 (Fig. 4d) and ZIP10 (Fig. 4e) exclusively in mitotic 
cells with no evidence of  pY705STAT3 presence in mitotic 
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cells (Fig. 4d and S3A). In contrast there was no detect-
able interaction between ZIP6 and  pY705STAT3 in any 
cells (Fig. 4d, S1D). Interestingly, there was a reduction of 
 pS727STAT3 bound to ZIP6 after cytokinesis (Fig. 4d, yel-
low arrow) suggesting dissociation of STAT3 from the com-
plex after mitosis (Supplementary Figure S3A). These data 
together establish that the ZIP6/ZIP10-mediated zinc influx 
at the start of mitosis changes the phosphorylation state of 
STAT3 from  pY705STAT3 to  pS727STAT3 which then binds 
in a complex to ZIP6 and ZIP10 exclusively during mitosis.
Interestingly, STAT3 is already known to bind to 
 p38Stathmin [41]. This form of Stathmin is present in mito-
sis not only to enable the microtubule reorganisation that is 
required for mitosis [41] but also as an essential requirement 
for both mitotic spindle assembly [42] and mitotic entry [39]. 
Having demonstrated that  pS727STAT3 and  pS38Stathmin 
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co-localise throughout the different stages of mitosis (Figure 
S4A) we also confirmed, by proximity ligation assay, that 
 pS727STAT3 and  pS38Stathmin bind exclusively in mitotic 
cells (Fig. 4f, S4B), supporting a role for  pS727STAT3 in 
stabilising Stathmin throughout mitosis and integrating the 
ZIP6/ZIP10/pS727STAT3/  pS38Stathmin complex into the 
established mitotic cascade.Using the ELM server [43] we 
discovered that the ZIP6 protein sequence has a predicted 
STAT3-binding site on the cytoplasmic loop (YESQ, resi-
dues 473–476) between transmembrane domains 3–4, which 
fits the consensus motif of a STAT3-binding site YxxQ [44] 
(Fig. 4g) and is highly conserved in the ZIP6 sequence in 
mammals (Fig. 4h). We generated a ZIP6 mutant Y473A to 
abolish this binding site and tested this by immunoprecipita-
tion (Fig. 4i, S2A, S2B). Probing for  pS727STAT3 in cells 
immunoprecipitated with V5 in cells transfected with both 
wild-type ZIP6 and other ZIP6 mutants showed reduced 
presence in the Y473A mutant (Fig. 4i), consistent with 
STAT3 binding to ZIP6 involving residue Y473. Interest-
ingly the nearby S475A mutant also showed an effect sug-
gesting a potential role for phosphorylation in the binding. 
ZIP10 also has a well conserved predicted STAT3-binding 
site YKQQ (512–524) in the corresponding region (Fig. 4j) 
suggesting the potential for ZIP10 binding as well. These 
data demonstrate the presence of  pS727STAT3 in mitotic 
cells which binds to both ZIP6 and ZIP10.
To dissect the temporal association of  pS727STAT3 
with the mitotic process, we imaged  pS727STAT3 in cells 
during mitosis (Fig.  5a). This revealed the presence of 
 pS727STAT3 at all stages of mitosis which was evident 
before cells were positive for  pS10HistoneH3 and also in 
cytokinesis when cells were still positive for  pS727STAT3 
yet negative for  pS10HistoneH3, indicating the prolonged 
presence of  pS727STAT3 throughout mitosis compared to 
 pS10HistoneH3 (Figure S3A, middle panel, white arrow). In 
contrast,  pY705STAT3 was absent in all mitotic cells (Figure 
S3A).
Furthermore, we also detected  pS727STAT3 staining in 
mitotic cells in vivo, as judged by  pS10HistoneH3 in the 
same cells using adjacent slices of human breast cancer 
(Fig. 5b). Additional in vivo staining of  pS727STAT3 was 
also seen in the mitotic cells of normal mouse intestine 
(Fig. 5c), suggesting a common process during mitosis that 
encompasses normal and disease states.
We have also gained some novel insight into how the 
S727 phosphorylation of STAT3, required during mitosis, 
is eliminated efficiently at the end of mitosis by removal 
of the C-terminus of STAT3, containing residue S727, by 
proteolytic cleavage. We examined the effect of zinc on 
mitotic progression by treatment with either a zinc chelator 
or zinc and also treatment with a STAT3 inhibitor for the 
last hour of nocodazole treatment. The treatment with zinc 
chelator or STAT3 inhibitor after treatment with nocodazole 
had no effect on  pS10HistoneH3 or STAT3 phosphorylation 
status (Fig. 5d and S3B for densitometry) once the cells 
had achieved mitosis, establishing that both STAT3 and 
zinc were required before cells reached mitosis. However, 
1-h incubation with 50 μM or 100 μM zinc after nocoda-
zole treatment had effects consistent with cells no longer 
in mitosis, as judged by loss of  pS10HistoneH3 and also 
the reversion of  pS727STAT3 to  pY705STAT3 (Fig. 5d). We 
then confirmed that these zinc-treated cells had progressed 
quicker through mitosis using a reduced zinc exposure time 
(Fig. 5e), noticing a loss of mitotic cell number as soon as 
15 min after zinc treatment. Importantly, these zinc-treated 
cells which had exited mitosis had lost the usual full length 
STAT3 band (Fig.  5d), showing only the C-terminally 
cleaved form of STAT3, thus removing a peptide contain-
ing residue S727 which is near the C-terminus [45]. This 
data demonstrates how C-terminal cleavage of STAT3 at the 
end of mitosis can efficiently stop S727 phosphorylation of 
STAT3 by removal of this residue and allow residue Y705 
to be available for phosphorylation, enabling the active tran-
scription factor form of STAT3 to be re-instated.
Cells require both ZIP6 and ZIP10 for maximal 
growth rate
In order to further examine the relationship between ZIP6 
and ZIP10 in the process of mitosis initiation, we compared 
NMuMg mouse breast cells to those that had ZIP6 removed 
by crispr/Cas9 technology [46]. Specifically, we show that 
NMuMg cells with ZIP6 knockout grow slower than wild-
type cells (Fig. 6a) and have considerably increased ZIP10 
levels compared to the wild-type cells (Fig. 6b), suggesting 
that the cells are able to some degree to compensate for the 
loss of ZIP6 by upregulating ZIP10. Additional confirmation 
of this mechanism is provided by the fact that it was possi-
ble to inhibit mitosis in wild-type NMuMg cells with either 
ZIP6 or ZIP10 antibody (Fig. 6c) whereas ZIP6 antibody 
failed to prevent mitosis in the ZIP6 knockout cells while 
the ZIP10 antibody treatment inhibited mitosis as expected 
(Fig. 6d). This adds further weight to the argument that 
ZIP10 can compensate for loss of ZIP6 to initiate mitosis, 
allowing the cells to divide, albeit at a lower rate than in the 
presence of ZIP6.
In order to examine whether any other ZIP family mem-
bers could be involved in this mitosis mechanism, especially 
when ZIP6 has been removed, we investigated whether ZIP5 
was involved as both ZIP6 and ZIP10 have been previously 
demonstrated by mass spectrometry screens to bind ZIP5 
[47] but no other ZIP transporters. Furthermore, ZIP5 is 
the only other LIV-1 family member present on the same 
arm of the SLC39A family phylogenetic tree as ZIP6 and 
ZIP10 [27] and therefore the prime candidate. We analysed 
the levels of ZIP5 in these wild-type NMuMg mouse cells to 
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examine whether ZIP5 increased when the cells were treated 
with nocodazole suggesting that ZIP5 may play a role during 
mitosis when either ZIP6 and ZIP10 are not available. We 
discovered that there was no difference between ZIP5 levels 
in mitotic or non-mitotic conditions. However, analysis of 
the ZIP5 levels in the ZIP6 knockout cells showed a sig-
nificant decrease of ZIP5 levels compared to wild-type cells 
(Fig. 6e) suggesting that ZIP5 is not involved in the growth 
of these cells and therefore unlikely to be partnering with 
ZIP10 to drive mitosis.
Inhibition of ZIP6/ZIP10 heteromer‑induced mitosis 
leaves cells in G2
Demonstrating that ZIP6-Y antibody and ZIP10 antibody 
treatments could inhibit cell growth we next investigated 
what happens to the antibody-treated cells that do not enter 
mitosis. FACS cell cycle analysis revealed a significant 
decrease in the G2/M population in MCF-7 cells treated with 
either the ZIP6-Y antibody (1:20 or 4 μg/ml) or the ZIP10B 
antibody (1:20 or 10  μg/ml) (Fig.  7a). The previously 
observed decrease in mitosis in this population would sug-
gest an increase of cells in G2. We assessed this by imaging 
for cyclin B1, a marker of mitosis and G2, in cells that had 
been treated with these antibodies using single cell fluores-
cence analysis (Fig. 7b). There was no statistical difference 
between the groups, neither was there any increase in apop-
tosis as judged by Western Blot of cleaved PARP on the 
same gel (Fig. 7c). We conclude from this data that cells 
treated with nocodazole and the ZIP6 or ZIP10 antibody 
have not become apoptotic but have remained in the G2 
stage of the cell cycle.
All this data together demonstrates a novel mechanism 
explaining the role of zinc in triggering mitosis. Influx of 
zinc into cells through the ZIP6/ZIP10 heteromer changes 
the phosphorylation of STAT3 and sets in motion the assem-
bly of a complex of proteins leading to microtubule reor-
ganisation and chromosome condensation, two key elements 
required for successful mitosis progression.
Discussion
Over fifty years after the original discovery that zinc deple-
tion arrests the cell cycle [48], we propose a molecular 
role of zinc in mitosis (Fig. 8). There is the formation of a 
zinc-dependant mitotic complex consisting of ZIP6, ZIP10, 
 pS727STAT3 and  pS38Stathmin that feeds into known 
mitotic pathways such as Stathmin-dependant microtubule 
reorganisation and HistoneH3-mediated chromosome con-
densation. Initially, STAT3 serves as a transcription fac-
tor (Fig. 8, stage 1) driving the gene expression of ZIP6 
and ZIP10 [49] [23], which forms a heteromer with ZIP10 
in the endoplasmic reticulum [29]. The N-terminal cleav-
age of ZIP6 is required for the ZIP6/ZIP10 heteromer to 
move to the plasma membrane (Fig. 8, stage 2) to initiate 
cell rounding [23] and import zinc into cells to start mitosis 
(Fig. 8, stage 3). This imported zinc triggers the formation 
of  pS727STAT3 from  pY705STAT3 (Fig. 8, stage 4), which 
remains bound to the ZIP6/ZIP10 heteromer throughout 
mitosis, preventing STAT3 transcriptional activity which is 
known to be turned off during mitosis [50]. Thus, STAT3 
in addition to being a transcription factor can moonlight 
as an effector of this heteromer and stabilise  pS38Stathmin 
throughout mitosis (Fig. 8, stage 5) which is critical for the 
formation of normal mitotic spindles [42]. The binding of 
 pS727STAT3 and  pS38Stathmin, confirmed by others [41], 
with the ZIP6/ZIP10 heteromer in a complex in mitosis, 
links  pS727STAT3 to the  p38Stathmin-driven microtubule 
re-organisation that is needed during mitosis (Fig. 8, stage 
6) and the  pS10HistoneH3 activation (Fig. 8, stage 7) that 
leads to chromosome condensation essential for mitosis 
(Fig. 8, stage 8).
The complex of ZIP6/ZIP10/pS727STAT3/pS38Stath-
min remains until the end of mitosis (Fig. 8, stage 9) when 
STAT3 is cleaved at the C-terminus, physically removing 
residue Ser727 (Fig. 8, stage 10), allowing STAT3 to revert 
to Tyr705 phosphorylation, the active transcription fac-
tor form of STAT3. This discovery therefore provides the 
Fig. 4  Both ZIP6 and ZIP10 bind  pS727STAT3 in mitosis. a Mitotic 
MCF-7 cells, positive for ZIP6-SC (red),  pS727STAT3 (green) and 
DAPI (blue), and above the plain of adherent cells, are enriched for 
ZIP6 and  pS727STAT3 (inset). b There was a Significant increase 
in  pS727STAT3 and decrease in  pY705STAT3 when mitosis was 
increased by nocodazole treatment (student t-test statistics). c A 
significant zinc-dependent increase in  pS727STAT3 in MCF-7 cells 
treated with 20  μM zinc (Zn) and 10  μM pyrithione (P) in serum-
free medium (SF) for 20  min and a corresponding decrease in 
 pY705STAT3. d PLA using ZIP6-SC and  pS727STAT3 antibodies in 
nocodazole-treated MCF-7 cells produces a significantly increased 
number of dots only in mitotic cells (white arrows), in contrast 
to ZIP6-SC and  pY705STAT3 antibodies which show negligible 
dots. Yellow arrow indicates less dots in cytokinesis. e PLA using 
 pS727STAT3 and ZIP10 cytoplasmic loop antibodies in nocodazole-
treated MCF-7 cells produces a significant increase in dots in mitotic 
cells (white arrows). f PLA using  pS38Stathmin and  pS727STAT3 anti-
bodies in nocodazole-treated MCF-7 cells produces increased dots 
only in mitotic cells (white arrows). g Schematic of residues around 
the STAT3-binding site in ZIP6 (Y473) showing potential phospho-
rylation sites. h The predicted STAT3-binding site YESQ, residues 
473–476, in ZIP6 (green box) is conserved in different species. i 
Immunoprecipitation with V5 antibody in cells transfected with ZIP6 
wild-type (WT) or sequence-verified mutants (Fig. S2A-B), all with 
a C-terminal V5 tag, demonstrates a significant decrease in binding 
to  pS727STAT3 in S475A and Y473A mutants. j Predicted STAT3-
binding site YKQQ, residues 521–524, in ZIP10 (green box) is con-
served in different species. All results in this figure represent at least 
three independent experiments and graphs are mean ± SD. Statistical 
significance was performed using ANOVA with Dunnett post-hoc 
and is shown as *(p < 0.05), **(p < 0.01) or ***(p < 0.001). Scale 
bar = 10 μm
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mechanism of how zinc is the essential trigger for mitosis 
and the ability of our antibodies to prevent this crucial zinc 
influx now provides novel new targets for proliferative dis-
eases such as cancer.
Our data confirm previous observations that zinc can 
bind to STAT3 resulting in decreased  pY705STAT3 [40] yet 
we also show a reciprocal increase in  pS727STAT3. This 
is the first time that  pS727STAT3 has been coupled to a 
mechanism for driving mitosis. Interestingly, the presence 
of  pS727STAT3 in mitosis has been observed by a whole 
genome mass spectrometry screen [51] of protein phos-
phorylation events during mitosis, consistent with the data 
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presented here. We also detected an inverse association of 
 pY705STAT3 and  pS727STAT3, which has been previously 
reported by others [52], although mitosis was not exam-
ined. Interestingly, transcription ceases during mitosis [53] 
and loss of  pY705STAT3, as mediated by zinc in mitosis, 
will terminate STAT3 transcriptional activities, preventing 
downstream signalling effects on multiple pathways for the 
duration of mitosis.
Most focus on STAT3 signalling is centred on 
 pY705STAT3, the transcription-promoting form of the pro-
tein [54–56], which drives many adverse cancer features 
such as epithelial-mesenchymal transition in HER2-posi-
tive breast tumours [57]. In contrast,  pS727STAT3 has been 
widely overlooked [58] despite having an essential role in 
mouse embryonic and perinatal growth [59] and in prolifera-
tion, optimal pluripotency and transition to neural commit-
ment of mouse embryonic stem cells [60]. Recently, how-
ever,  pS727STAT3 was discovered to promote prostate cancer 
[61] and chronic lymphoid leukaemia [62] independently of 
 pY705STAT3 and together with  pY705STAT3,  pS727STAT3 
associates with poor clinical outcome in glioblastoma [63]. 
Furthermore, the appearance of  pS727STAT3 at the start of 
mitosis suppresses the expression of G1 cell cycle nega-
tive regulators  p21CIP1/WAF1 and  p27Kip1, maintaining CDK1 
activity during mitosis and providing evidence for a role 
in mitotic onset and progression [64]. Recently, the level 
of  pS727STAT3 in glioblastoma has been positively cor-
related with poor outcome [63], consistent with a role for 
 pS727STAT3 in mitosis. Despite these data and the knowl-
edge that most cancers have increased expression of STAT3, 
no molecular mechanism has previously linked STAT3 to 
involvement in the onset of mitosis.
The discovery of the role of the ZIP6/ZIP10 heter-
omer in triggering mitosis has enabled us to use ZIP6 or 
ZIP10 blocking antibodies to prevent mitosis, an important 
discovery to help target cell division in diseases of aberrant 
proliferation, including cancer. These antibodies bind to the 
extracellular portion of the ZIP6/ZIP10 heteromer on the 
plasma membrane and each of them alone was able to block 
the mitosis-triggering zinc influx in a concentration-depend-
ent manner confirming the vital nature of this zinc influx to 
mitosis initiation. Importantly, the IgG isotype control did 
not have any effect on mitosis, confirming a ZIP6/ZIP10 
specific effect. The new crystal structure of a ZIP transporter 
[65], has produced a predicted structure for the extracellular 
region of the ZIP4 dimer [66] which confirmed the essen-
tial nature of this extracellular region for full zinc transport 
activity and explains how the ZIP6 or ZIP10 antibodies can 
potentially inhibit the ZIP6/ZIP10 heteromer by binding the 
N-terminus and either blocking the zinc influx or interfer-
ing with activation such as protease cleavage. Since prion 
proteins have descended from ZIP6 and ZIP10 [67] and as a 
result show much similarity to the N-terminus of ZIP6 and 
ZIP10, including the ability to influx zinc into cells [68], it 
is likely that protease cleavage plays a role in the function of 
ZIP6 and ZIP10. Interestingly, ZIP6 and ZIP10 antibodies 
to different epitopes have also been demonstrated to inhibit 
meiosis [69] showing a mutual need for zinc influx in both 
cell division processes. We have additionally established 
that ZIP6/ZIP10 antibody treatment inhibits mitosis in tri-
ple negative breast cancer cell lines (Fig. 2), a form of breast 
cancer with poor treatment and prognosis, offering potential 
for a new treatment.
Both ZIP6 and ZIP10 independently have been associ-
ated with cancers, especially those with poor prognosis, 
which is consistent with this newly discovered role for ZIP6 
and ZIP10 in driving mitosis. ZIP6 has been implicated in 
oesophageal cancer [70, 71], breast cancers [23] prostate 
cancer [72], consistently being associated with more aggres-
sive forms of the diseases. Similarly, ZIP10 over-expression 
has been correlated to aggressiveness in renal cell carcinoma 
[36], metastatic breast cancer [35], gastric cancer [73] and 
it is one of the 7 zinc transporter genes upregulated in acti-
vated colon tumour cells [24], compatible with our proposed 
role for ZIP10 in cell division.
Our newly discovered mechanism requires zinc influx 
specifically through the ZIP6/ZIP10 heteromer into cells 
to trigger mitosis. We have demonstrated increased fluores-
cence of the zinc-dependant Fluozin-3 dye in mitotic cells 
consistent with observations by others using synchrotron 
x-ray fluorescence microscopy [74] demonstrating a three-
fold zinc increase in mitotic versus interphase cells. Further-
more, zinc accumulates in the tail tip of zebrafish embryos, 
the key area contributing to embryonic growth [75], a pro-
cess that requires much cell division and a further example 
of the zinc requirement for cell division.
Stathmin is prometastatic in colon cancer, a process that 
requires  pS38Stathmin and knockdown of Stathmin was 
Fig. 5  pS727STAT3 is present throughout mitosis and is cleaved for 
mitosis exit. a  pS727STAT3 (green) is increased in all stages of mito-
sis in cells stained with DAPI (blue) and α-tubulin (red) compared 
to interphase. Scale bar = 10  μm. b Adjacent slices of breast can-
cer tissue show both  pS10HistoneH3 and  pS727STAT3 in the same 
mitotic cells (red staining). c Both  pS10HistoneH3 and  pS727STAT3 
are present in mitotic cells within the crypts of normal mouse intes-
tine (brown staining). d Reduction of zinc (zinc chelator TPEN) or 
STAT3 inhibition for 1 h after cells were pre-treated with nocodazole 
for 19 h has no effect on mitosis whereas zinc–treated samples move 
through mitosis faster, loosing  pS10HistoneH3 and  pS727STAT3. Full-
length STAT3 is C-terminally cleaved when cells move out of mito-
sis (zinc-treated lanes), physically removing residue S727. e Mitotic 
count (positive for  pS10HistoneH3) was performed in cells treated 
with nocodazole for 19 h plus 100 μM zinc and 10 μM pyrithione for 
0-60mins. Cells begin to progress through mitosis after only 15 min 
zinc treatment. Results are from at least three experiments. Statistical 
significance comparing the zinc treatment to the non- treated samples 
(CON) was performed using ANOVA with Dunnett post-hoc and is 
shown as *(p < 0.05) or **(p < 0.01)
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shown to reduce STAT3 [76], confirming an association of 
these two proteins. Furthermore, as  pS38Stathmin is critical 
for the formation of the normal mitotic spindle [42], its bind-
ing to  pS727STAT3 during mitosis will stabilise the form of 
Stathmin that enables microtubule reorganisation [41], an 
essential component of the mitosis process. Dephosphoryla-
tion of  pS38Stathmin is required before cells can exit mito-
sis [42] which suggests a role for STAT3 C-terminal cleav-
age in dissociating the complex and allowing mitosis exit. 
C-terminal cleavage of STAT3 will remove residue S727 
[45] enabling STAT3 phosphorylation on Y705, the active 
transcription factor form of STAT3, which is required on exit 
from mitosis. Furthermore, PP2A, which dephosphorylates 
 pS727STAT3 [77] and is inhibited by zinc [78], becomes acti-
vated at the end of mitosis when zinc levels decrease [79], 
providing a secondary mechanism for  pS727STAT3 removal 
at the end of mitosis.
Knowledge that STAT3 is required for the expres-
sion of both ZIP6 [38] and ZIP10 [29] in the gastrula 
organiser coupled with our discovery of the involvement of 
 pS727STAT3 in mitosis defines the previously unresolved 
role for this form of STAT3 in cells and explains why STAT3 
is the only STAT gene to be embryonic lethal [80]. Impor-
tantly, not only do these STAT3 knockout cells die before 
gastrulation, the stage of embryogenesis that requires ZIP6 
[38], STAT3 is expressed in the visceral endoderm, the part 
of the embryo that takes part in exchange of nutrients such 
as zinc. Our data combines with this to support the crucial 
role for ZIP6 as the means to bring zinc into cells to initiate 
mitosis in a STAT3-dependant manner. Given that STAT3 is 
known to be phosphorylated on residue S727 by many dif-
ferent kinases [52, 81, 82], it is yet to be determined whether 
zinc causes pS727 phosphorylation of STAT3 directly or 
through activation of one of these kinases. We have however 
established that  pS727STAT3 binds ZIP6 on residue Y473, a 
consensus motif of a STAT3-binding site YxxQ [44].
The 3 key molecules in this zinc-driven mitosis pathway, 
ZIP6, ZIP10 and  pS727STAT3, now offer new therapeutic 
Fig. 6  Cells require both ZIP6 
and ZIP10 for maximal growth 
rate. a ZIP6 knockout NMuMg 
cells (NMuMg ZIP6 ko) grow 
significantly slower than wild-
type cells. b ZIP10 level is sig-
nificantly increased in NMuMg 
ZIP6 knockout cells compared 
to wild-type by Western Blot. 
Both ZIP6 and ZIP10 antibodies 
are able to significantly inhibit 
mitosis in NMuMg wild-type 
cells (c) whereas ZIP6 antibody 
is unable to inhibit mitosis in 
ZIP6 knockout cells and ZIP10 
antibody can (d). e Western 
blot comparing levels of ZIP5 
in wild-type and ZIP6 knockout 
NMuMg cells. There is a signif-
icant reduction in ZIP5 levels in 
the ZIP6 knockout cells even in 
the presence of nocadazole. All 
results are from at least three 
experiments. Statistical signifi-
cance comparing the results to 
controls was performed using 
ANOVA with Dunnett post-hoc 
and is shown as *(p < 0.05) or 
**(p < 0.01)
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opportunities for inhibition of cell division in proliferative 
diseases such as cancer.
Materials and methods
Materials, antibodies and treatments
Antibodies used were ZIP6-SC (E-20, SC-84875), 
 pS727STAT3 (SC-8001-R and SC-136193),  pY705STAT3 
(SC-7993-R), total STAT3 (SC-8019), normal mouse 
IgG (sc-2025), normal rabbit IgG (sc-2027) and GAPDH 
(SC-32233) from Santa Cruz Biotechnology; α-tubulin 
(DM1A, #3873S),  pS10HistoneH3 (#9706S and #3377) and 
 pS38Stathmin (#4191) from Cell Signalling Technology; 
mouse V5 from Invitrogen; rabbit V5 (Ab9116), mouse/
rabbit apoptosis cocktail (ab136812) from Abcam; β-actin 
(A5316), ZIP10 cytoplasmic loop antibody (SAB1401780) 
from Sigma-Aldrich (referred to as ZIP10S antibody). Treat-
ments used were 100 ng/mL nocodazole (Sigma-Aldrich, 
M1404) for 20 h, 200 μM STAT3 inhibitor cell-permea-
ble peptide (Calbiochem, 573,096), 5 μM camptothecin 
(Sigma- Aldrich) for 20 h and 20–100 μM zinc with 10 μM 
sodium pyrithione (Sigma-Aldrich), and 25 or 50 μM TPEN 
(Sigma-Aldrich). Mitosis inhibition experiments were per-
formed using mouse monoclonal antibody generated by Bio-
genes to ZIP6 residues 240–253(ZIP6-Y) and rabbit poly-
clonal antibody to ZIP10 residues 46–59 (ZIP10B) which 
were added to cells in culture for 20 h in the presence of 
nocodazole.
Cell lines and Immunohistochemistry
MCF-7 cells were cultured as previously described [26]. 
NMuMG cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco) containing 4.5 g/L glucose sup-
plemented with 10% foetal calf serum (FCS), 200 mM 
l-glutamine, antibiotics (10 IU/mL penicillin, 10 휇g/mL 
streptomycin) and amphotericin B (2.5 휇g/mL) (Gibco). For-
malin-fixed paraffin-embedded breast cancer samples were 
dewaxed and rehydrated before incubated with  pS727STAT3 
(SC-8001-R, 1/650) or  pS10HistoneH3 (#3377, 1/30) anti-
bodies for 2 h and detected with Dako Envision #K4011 rea-
gent. Two-minute pressure cooker at pH9 in Tris base plus 
EDTA was used for antigen retrieval. The primary breast 
cancer material used had correct ethical approval (REC 
reference number C2020313). Immunohistochemistry of 
mouse intestinal tissue was previously described [83].The 
ZIP6 knockout cells were made from CRISPR-Cas9-edited 
mouse mammary NMuMG cells as previously described 
[46] and were a kind gift from G. Schmitt-Ulms.
Plasmids and transfections
The generation of recombinant constructs for ZIP6/LIV-1/
SLC39A6 [84], ZIP7/HKE4 [85] and ZIP10 [29] with C-ter-
minal V5 tags using vector pcDNA3.1/V5-His-TOPO has 
been previously described. ZIP6 mutants (Y473A, S471A, 
S475A and S478A, S479A) were generated from the above 
plasmid and confirmed by sequencing (Figure S2A, S2B). 
Cells were transfected with Lipofectamine-2000 (Life Tech-
nologies) for 16 h as described [23].
SDS‑PAGE, western blotting 
and immunoprecipitation
Cells were harvested, washed with PBS, lysed for 1 h at 4 °C 
with lysis buffer pH7.6 (50 mM Tris, 150 mM NaCl, 5 mM 
EGTA and 1% Triton X-100) with protease inhibitor cock-
tail for mammalian cells (Sigma-Aldrich) and phosphatase 
inhibitors (2 mM sodium orthovanadate and 50 mM sodium 
fluoride). Protein was measured using Bio − Rad/Bradford 
dye − binding protein micro assay. Western Blot results of 
40 μg/lane from three separate experiments were normal-
ized to GAPDH values. For immunoprecipitations, 500 μg 
of protein was incubated with 5 μg of antibody overnight and 
20 μL of EZview Red Protein A Affinity Gel (Sigma) for 4 h 
prior to washing and SDS-Page.
Fluorescence microscopy and FACS analysis
1 × 105 cells were grown on 0.17 mm thick coverslips for 
5–7 days prior to transfection. Coverslips were fixed and pro-
cessed as previously described [13]. For zinc imaging, cells 
were loaded with 5 μM Fluozin-3 (Invitrogen) for 30 min at 
37 °C. For FACS analysis using a Becton–Dickinson FAC-
SVerse, non-adherent cells collected by mitotic shake-off 
and adherent cells harvested by trypsinisation were loaded 
with 5 μM Fluozin-3 (Invitrogen) for 30 min followed by 
30 min recovery in medium. For cell cycle analysis, cells 
were fixed in 70% ethanol overnight followed by DNA stain-
ing with 20 µg/mL propidium iodide (Sigma-Aldrich) plus 
0.2 µg/mL DNase − free RNase A and 0.1% Triton X-100 in 
PBS at 37 ºC for 20 min before FACS analysis and analysed 
with FlowJo Software version 10 using Watson pragmatic 
algorithm. Scale bar is 10 μm.
Proximity ligation assay (PLA)
Cells on eight-well chamber slides (Lab-Tek, Fisher) were 
fixed followed by PLA using Duolink red kit (Sigma) 
as described previously [13] and where red fluorescent 
dots indicate two molecules binding. Dots per cell were 
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determined with ImageTool software (Olink) using at least 
12 separate images from at least three different experiments 
and presented as average values ± standard errors.
Statistical analysis
Statistical analysis was performed using ANOVA with Post-
Hoc Dunnett and Tamhane tests. Significance was assumed 
with * = p < 0.05, *** = p < 0.01, *  *  *  = p < 0.001. Error 
bars are standard deviation (SD) with at least 3 different 
experiments.
Acknowledgements KMT acknowledges the support of a Wellcome 
Trust University Research Award [grant number 091991/Z/10/Z]. 
KMT, TN, SZ and OO are members of the European COST action 
ZINC-NET. SZ was supported by Tenovus Cancer Care [grant num-
ber PhD 2015/L31], OO was supported by the Life Sciences Research 
Network Wales. The authors thank Gerold Schmitt-Ulms for the kind 
gift of the ZIP6 knockout NMuMG cells. The authors acknowledge 
the additional support of the Breast Cancer Molecular Pharmacology 
Group. We thank Pauline Finlay for the breast cancer immunocyto-
chemistry and Ute Rockinger and Matt Dibble for some fluorescent 
microscopy.
Fig. 7  ZIP6 or ZIP10 inhibited cells remain in G2 and are not apop-
totic. a FACS cell cycle analysis reveals a significant decrease in 
the G2/M population in MCF-7 cells treated with either ZIP6-Y 
(2  μg/ml) or ZIP10B (5.25  μg/ml) antibody. The graphs show the 
mean of n = 3 ± SE. b Imaging differences between mitotic cells 
 (pS10HistoneH3, green) and those in G2/M stages of the cell cycle 
(cyclinB1, red) when treated with ZIP6-Y antibody, ZIP10B antibody 
and/or nocodazole for 20 h. The percentage of cells positive for cyclin 
B1 is shown as a bar graph. No statistical significance was revealed. 
c There is no increase in apoptotic cells when treated with ZIP6-Y 
(4  μg/ml) or ZIP10B (10.5  μg/ml) antibodies as judged by Western 
Blot of cleaved PARP and a positive control of apoptosis (camptoth-
ecin 5 μM). All results are from at least three experiments. Statisti-
cal significance comparing the + ve to the different cell treatment and 
the non- treated samples (CON) was performed using ANOVA and is 
shown as *(p < 0.05) or **(p < 0.01). No statistical significance was 
found between the samples treated with nocodazole ± ZIP6 or ZIP10 
antibody and the non-treated samples (CON)
◂
Fig. 8  Schematic of how zinc triggers mitosis. Schematic demonstrat-
ing a model of how the ZIP6/ZIP10 heteromer imports zinc into cells 
to trigger mitosis. STAT3 driven ZIP6 [1] is located on the endo-
plasmic reticulum membrane where it forms a heteromer with ZIP10 
[29] until the correct stimulus [2] for ZIP6 N-terminal cleavage and 
relocation to the plasma membrane [23]. Plasma membrane located 
ZIP6/ZIP10 heteromer causes cell rounding and influxes zinc to trig-
ger mitosis [3]. This zinc triggers formation of  pS727STAT3 from 
 pY705STAT3 [4], which binds to the ZIP6/ZIP10 heteromer [5]. The 
binding of  pS38Stathmin to  pS727STAT3 as part of the ZIP6/ZIP10 
heteromer mitosis complex enables the  pS38Stathmin-driven micro-
tubule re-organisation needed for mitosis [6] and the activation of 
 pS10HistoneH3 [7] which leads to condensation of chromosomes [8]. 
Between prophase and metaphase, ZIP6 is N-terminally cleaved for 
a second time and the mitosis complex remains during mitosis [9]. 
The C-terminus of STAT3 is cleaved at the end of mitosis to remove 
Ser727 [10] allowing Tyr705 to become phosphorylated and restore 
STAT3 transcriptional activity
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